• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

PharmaMar - Articles and news items

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

PharmaMar initiates a phase III ATLANTIS study for small cell lung cancer

Industry news / 2 August 2016 / PharmaMar

PharmaMar announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer after the failure of one prior platinum-containing line.

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +